Bristol widens drug-licensing partnership with Ono

09/21/2011 | Reuters

Bristol-Myers Squibb gained rights to investigational cancer immunotherapy BMS-936558/ONO-4538 in all countries except Taiwan, Japan and South Korea through an expanded agreement with Ono Pharmaceutical. Bristol already had exclusivity in North America. In exchange, Ono gets co-development and -marketing rights in Japan to Orencia, Bristol's rheumatoid arthritis drug.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA